Biomedical Engineering Reference
In-Depth Information
175. Loo TW, Clarke DM. 2005. Do drug substrates enter the common drug-binding pocket
of P-glycoprotein through “gates”? Biochem Biophys Res Commun 329:419-422.
176. Loo TW, Bartlett MC, Clarke DM. 2004. The drug-binding pocket of the human multidrug
resistance P-glycoprotein is accessible to the aqueous medium. Biochemistry 43:12081-
12089.
177. Loo TW, Bartlett MC, Clarke DM. 2003. drug-binding in human P-glycoprotein causes
conformational changes in both nucleotide-binding domains. J Biol Chem 278:1575-
1578.
178. Loo TW, Bartlett MC, Clarke DM. 2003. Permanent activation of the human P-
glycoprotein by covalent modification of a residue in the drug-binding site. J Biol Chem
278:20449-20452.
179. Ramachandra M, Ambudkar SV, Chen D, Hrycyna CA, Dey S, Gottesman MM, Pastan
I. 1998. Human P-glycoprotein exhibits reduced affinity for substrates during a catalytic
transition state. Biochemistry 37:5010-5019.
180. Sauna ZE, Ambudkar SV. 2001. Characterization of the catalytic cycle of ATP hydrolysis
by human P-glycoprotein. The two ATP hydrolysis events in a single catalytic cycle are
kinetically similar but affect different functional outcomes. J Biol Chem 276:11653-
11661.
181. Qu Q, Chu JW, Sharom FJ. 2003. Transition state P-glycoprotein binds drugs and modula-
tors with unchanged affinity, suggesting a concerted transport mechanism. Biochemistry
42:1345-1353.
182. Chen M, Abele R, Tampe R. 2003. Peptides induce ATP hydrolysis at both subunits of
the transporter associated with antigen processing. J Biol Chem 278:29686-29692.
183. Ambudkar SV, Kim IW, Sauna ZE. 2006. The power of the pump: mechanisms of action
of P-glycoprotein (ABCB1). Eur J Pharm Sci 27:392-400.
184. Higgins CF, Linton KJ. 2004. The ATP switch model for ABC transporters. Nat Struc
Biol 11:918-926.
185. Sauna ZE, Smith MM, Muller M, Kerr KM, Ambudkar SV. 2001. The mechanism of action
of multidrug-resistance-linked P-glycoprotein. J Bioenerg Biomembr 33:481-491.
186. Sauna ZE, Muller M, Peng XH, Ambudkar SV. 2002. Importance of the conserved Walker
B glutamate residues, 556 and 1201, for the completion of the catalytic cycle of ATP
hydrolysis by human P-glycoprotein (ABCB1). Biochemistry 41:13989-14000.
187. Lin JH, Yamazaki M. 2003. Clinical relevance of P-glycoprotein in drug therapy. Drug
Metab Rev 35:417-454.
188. Lin JH, Yamazaki M. 2003. Role of P-glycoprotein in pharmacokinetics: clinical impli-
cations. Clin Pharmacokinet 42:59-98.
189. Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DK, Borst P,
Nooijen WJ, Beijnen JH, van Tellingen O. 1997. Limited oral bioavailability and active
epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc
Natl Acad SciUSA94:2031-2035.
190. Sikic BI, Fisher GA, Lum BL, Halsey J, Beketic-Oreskovic L, Chen G. 1997. Modulation
and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother
Pharmacol 40 (Suppl):S13-S19.
191. Choo EF, Leake B, Wandel C, Imamura H, Wood AJJ, Wilkinson GR, Kim RB. 2000.
Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1
protease inhibitors into brain and testes. Drug Metab Dispos 28:655-660.
Search WWH ::
Custom Search